Shu-Len Liu

Title: Innovations by Shu-Len Liu in Factor VIII Therapeutics

Introduction

Shu-Len Liu is a notable inventor based in Cerritos, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents for treating Factor VIII deficiencies. His work has implications for patients suffering from hemophilia A and those with Factor VIII inhibitors.

Latest Patents

Shu-Len Liu holds 2 patents that focus on innovative methods for treating Factor VIII deficiencies. His latest patents include "Activated factor VIII as a therapeutic agent and method of treating" and "Ultrapurification process for factor VIII." The first patent describes a stabilized and activated Factor VIII used as a therapeutic agent to treat patients with Factor VIII deficiency. This includes hemophilia A patients and those with inhibitors that block the hemostatic activity of Factor VIII. The second patent outlines a process for purifying Factor VIII:C, which involves a series of steps to ensure the effective separation of contaminants from the therapeutic agent.

Career Highlights

Shu-Len Liu is associated with Baxter International Inc., a leading company in the healthcare sector. His work at Baxter has allowed him to focus on developing advanced therapeutic solutions for patients with bleeding disorders. His contributions have been instrumental in enhancing treatment options for individuals with Factor VIII deficiencies.

Collaborations

Shu-Len Liu has collaborated with notable colleagues such as Joseph Edward Curtis and Sam L Helgerson. These collaborations have fostered an environment of innovation and have led to significant advancements in the field of biotechnology.

Conclusion

Shu-Len Liu's work in the development of Factor VIII therapeutics showcases his commitment to improving patient care in the field of hemophilia treatment. His patents and collaborations reflect a dedication to innovation and excellence in biotechnology.